From Weight-Loss Pills to Retail Deals: Navigating the 2026 Consumer Landscape

In this episode, the team discusses the major takeaways fromtwo of the year’s most influential investor events: the J.P. Morgan Healthcare Conference and the ICR Consumer Conference. The team analyzes the shifting landscape of high-cap pharma M&A, the commercial launch of anti obesitypills from Novo Nordisk and Eli Lilly, and the rise of targeted "rifle shot" cancer treatments. Turning to the consumer sector, they examine a holiday retail season defined by deep discounting, the impact of GLP-1 drugs on restaurant margins, and the ongoing leadership drama at Lululemon amidst potential Supreme Court rulings on tariffs. Please note that some of the companies discussed in thispodcast may be held in an AMI strategy or in personal accounts, including LULU, ANF, AEO, URBN, CMG, DRI, JPM, ICR, MRK, JNJ, NVO, LLY, BSX, PEN, SYK, NARI, CGON, and VRNA.